



SB 764: Ending Pay-for-Delay

Prohibiting Pay-to-Play Monopolies Over Name Brand Drugs

While the skyrocketing cost of prescription medications continues to hurt the people, employers, and state and local governments who have no choice but to pay the price, **brand-name pharmaceutical companies are working in the background to keep costs as high as possible.**

Pharma manufacturers often pay generic drug manufacturers to delay distribution of generic drugs at a substantially lower cost. This gives name brands the ability to hold a monopoly on their drugs, enriching their profits while thousands of Oregon seniors and families struggle to afford their medications and make ends meet.

By passing SB 764, Oregon has a chance to hold name brand pharmaceutical companies accountable for this common practice that aids the steady increase in prescription drug costs year after year.

Prohibiting pay-for-delay of generic drugs will ensure less expensive medications become available sooner, and give the State of Oregon power to take action against pharmaceutical companies that fail to comply.

Trusted organizations are supporting SB 764:



Learn more about OCAP and our mission at AffordableRxNow.org

For more information contact Dave Hunt (dave@columbiapublicaffairs.com or 503-810-8387) or Taylor Sarman (taylor@columbiapublicaffairs.com or 541-910-5711)